A Phase 1 Study of Intraperitoneal MCY-M11 Therapy for Women With Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects With Peritoneal Mesothelioma With Recurrence After Prior Chemotherapy
Phase of Trial: Phase I
Latest Information Update: 10 Oct 2018
At a glance
- Drugs MCY-M11 (Primary)
- Indications Adenocarcinoma; Fallopian tube cancer; Mesothelioma; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- Sponsors MaxCyte
- 10 Oct 2018 According to a MaxCyte media release, MaxCyte Commences Dosing in this study.
- 30 Aug 2018 Status changed from not yet recruiting to recruiting.
- 01 Aug 2018 Status changed from planning to not yet recruiting.